An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients.
Postprandial hyperglycemia and hyperlipidemia are considered risk factors for cardiovascular disease. This study was designed to elucidate whether improving the postprandial state by voglibose, an alpha-glucosidase inhibitor, leads to the reduction of oxidative stress markers and soluble adhesion molecules in obese type 2 diabetic patients. A total of 30 Japanese obese type 2 diabetic patients were randomly assigned and treated for 3 weeks with either diet alone (the control group) or diet plus voglibose (0.9 mg daily) (the voglibose group) (n=15 each). Analysis of the diurnal metabolic profiles revealed a significant reduction of postprandial hyperglycemia and hyperlipidemia in the voglibose group relative to the control group (P<.05), despite the similar improvement in body mass index and hemoglobin A(1c) in both groups. Voglibose also decreased significantly the plasma levels of soluble intercellular adhesion molecule 1 and urinary excretion of 8-iso-prostaglandin F(2)alpha and 8-hydroxydeoxyguanosine (P<.01) and C-reactive protein (P<.05) relative to the control group. In conclusion, this study represents the first demonstration that voglibose reduces oxidative stress generation and soluble intercellular adhesion molecule 1 in parallel with the reduction of postprandial hyperglycemia and hyperlipidemia in obese type 2 diabetic patients.
Satoh
Noriko
N
Clinical Research Institute for Endocrine Metabolic Disease, National Hospital Organization, Kyoto Medical Center, Fushimi-ku, Kyoto 612-8555, Japan.
Shimatsu
Akira
A
Yamada
Kazunori
K
Aizawa-Abe
Megumi
M
Suganami
Takayoshi
T
Kuzuya
Hideshi
H
Ogawa
Yoshihiro
Y
D000328:Adult; D015415:Biomarkers / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy; D006949:Hyperlipidemias / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology; D007294:Inositol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood*; D007564:Japan; D008297:Male; D008875:Middle Aged; D009765:Obesity; D018384:Oxidative Stress / Q000187:drug effects*; D016037:Single-Blind Method; D012995:Solubility
D015415:Biomarkers; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D018799:Intercellular Adhesion Molecule-1; D007294:Inositol; C102817:voglibose